PCT/GB 99/01499
09/719909

The Patent Office

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 3 June 1999

Patents Form 1/77

Patents Act 1977
(Rule 16)

The Patent Office

1/77

30JUN98 E371921-18 D00060
P01/7700 25.00 - 9814039.5

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference — SJK/BP5638093

2. Patent application number *(The Patent Office will fill in this part)* — **9814039.5**

THE PATENT OFFICE F 29 JUN 1998 RECEIVED BY HAND

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

UNIVERSITY COLLEGE LONDON
Gower Street
London
WC1E 6BT
GB

Patents ADP number *(if you know it)* 07422025001

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention — MATERIALS AND METHODS RELATING TO THE PREVENTION OR TREATMENT OF ISCHAEMIA-REPERFUSION INJURY

5. Name of your agent *(if you have one)* — MEWBURN ELLIS

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

YORK HOUSE
23 KINGSWAY
LONDON
WC2B 6HP

Patents ADP number *(if you know it)* 109006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month /year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	19
Claim(s)	0
Abstract	0
Drawing(s)	8

10. If you are also filing any of the following, state

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	0
Request for preliminary examination and search *(Patents Form 9/77)*	0
Request for substantive examination *(Patents Form 10/77)*	0
Any other documents *(Please specify)*	0

11. I/We request the grant of a patent on the basis of this application.

Signature: Newburn Ellis

Date: 26 June 1998

12. Name and daytime telephone number of person to contact in the United Kingdom: SIMON KIDDLE 0117 9266 411

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed it it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.

Materials and Methods Relating to the Prevention or Treatment of Ischaemia-Reperfusion Injury

Field of the Invention

The present invention relates to material and methods relating to the prevention or treatment of ischaemia-reperfusion injury, and in particular to compositions comprising inositolphosphoglycans (IPGs) and their medical use in the prevention or treatment of ischaemia.

Background of the Invention

The search for novel therapies for ischaemic-reperfusion injury in the heart has been a subject of intense research, both for recovery from open-heart surgery, where the limited capacity for the heart to survive ischaemia is a well researched problem (Stanley et al, 1997), and from the viewpoint of modulating the extent of damage incurred during episodes of cardiac ischaemia (Stanley et al, 1997). It is also well established that the incidence of coronary heart disease is a major factor in the morbidity and mortality of diabetic patients (Fuller et al, 1983; Hillier et al, 1988). There is also evidence that standard drugs for the treatment of diabetes of the sulphonylurea group may have negative effects, including those on K^+ channel function (Smits & Thien, 1995; Muhlhauser et al, 1997).

The complexity of the events following ischaemia-reperfusion is such that there is a very wide ranging database of potential therapeutic and cardioplegic agents targeting differing aspects of the cascade leading to damage to cardiac function. It has been apparent from work as early as the 1960s (Danforth et al, 1960; Berne, 1963) to the present (Zimmer, 1996; Houston et al, 1997) that a key feature of the cascade of interlinked biochemical events following ischaemic-reperfusion injury centres on the loss of adenine nucleotides from the myocardium. There is, thus, an absolute requirement for the restitution of the intracellular ATP concentration

and the energy charge of the cell in order to restore normal cardiac function.

Adenine nucleotide synthesis can occur via utilization or reutilisation of adenine nucleotide breakdown products via the salvage pathway, or via *de novo* synthesis from small molecular weight precursors (see the scheme shown in figure 5). The former is the most effective in terms of energy requirement (Mangano, 1997; Meldrum et al, 1997).

However, in addition to the requirement for the purine ring, a supply of phosphoribosylpyrophosphate (PRPP) is essential both for the salvage and *de novo* routes of synthesis; this latter compound is, in turn, subject to tight regulation and is dependent upon a supply of ribose-5-phosphate (Kunjara et al, 1987). Zimmer (1980) demonstrated that restitution of myocardial adenine nucleotides was accelerated by ribose, as was the normalisation of depressed heart function in rats (Zimmer, 1983). This author stated that "The advantage of ribose over other metabolic interventions is that is does not affect the haemodynamics of the heart with an ultimate change in oxygen demand and that is has no vasoactive properties which may result in afterload alterations".

Recently, Zimmer (1996) reported that in two *in vivo* rat models, the overloaded and catecholamine-stimulated heart and the infarcted heart, the normalisation of the cardiac adenine nucleotide pool by ribose was accompanied by improvement in global heart function. Further, the combined treatment with ribose and adenine or inosine in isoproteronal-treated rats was more effective in the restoration and completely restored the ATP level within a shorter period of time than either treatment alone.

Summary of the Invention

While the results showing the effect of repletion of cardiac ATP are encouraging, the prior art approaches described above suffer from the disadvantage that the biosynthetic pathways themselves require ATP, as does the reconversion of AMP to ADP and ATP, the required ATP being the very compound in short supply. Further, as mentioned above, the complexity of the biochemistry associated with ischaemia means that it is not clear from the prior art how alternative approaches could avoid this problem.

The present invention relates to the finding that inositolphosphoglycans (IPGs), and in particular P-type IPGs or their synthetic analogues, can be used to generate ATP from ADP while helping to avoid the production of toxic byproducts and helping to minimise the ATP requirement for the process. Thus, compositions comprising IPGs can be used to prevent or treat ischaemia-reperfusion, in particular in conditions where there is a reduction or risk of reduction in cellular ATP levels, e.g. in cardiac ischaemia, in surgery (especially heart or transplant surgery), in preserving organs for transplantation, in the treatment of stroke and as an anti-apoptosis agent to protect against cell death (especially in muscle cells).

Accordingly, in a first aspect, the present invention provides the use of an inositolphosphoglycan (IPG) for the preparation of a medicament for the treatment of ischaemic-reperfusion injury.

The IPGs present in the medicament can be P- or A-type IPGs, or synthetic analogues of them. The production of IPGs and IPG analogues is discussed further below. Preferably, the IPG is a P-type IPG or a P-type synthetic analogue.

The present invention is based on the realisation that an alternative approach to the problem of increasing the energy generating systems of the cell is to employ the mitochondrial oxidative restoration system, in particular by the regulation of the key enzyme for the entry of pyruvate into the tricarboxylic acid cycle, pyruvate dehydrogenase. Accordingly, the present proposal centres upon the use of naturally occurring activators of pyruvate dehydrogenase phosphatase, the inositolphosphoglycans, to promote the conversion of pyruvate dehydrogenase to the active form, thereby enhancing the rephosphorylation of AMP and ADP.

Advantageously, the medicament can include one or more other components, in combination with the IPGs, for use in the treatment of ischaemia-reperfusion injury as described herein. Among the agents to be used in combination with IPGs from different sources are:

(1) Adenosine and purine compounds as precursors of ATP and as modulators of TNFα action (see Bouchard & Lamontagne, 1998; de Jong et al, 1997; Meldrum et al, 1997).

(2) Ribose as a precursor of PRPP (see Kunjara et al, 1987; Zimmer, 1996).

(3) Nicotinamide and derivatives to prevent the loss of NAD and ATP by inhibition of poly-ADP ribose synthetase (see Bromme & Holz, 1996; Zingarelli et al, 1996; Gilad et al, 1997; Thiememann et al, 1997).

(4) Ca^{2+} uptake inhibitors (see Ferrari et al, 1996; Loh et al, 1998; Russ et al, 1996).

(5) Addition of IPGs to established cardioplegic

solutions (see Choong and Gavin, 1996; Bozkurt et al, 1997).

(6) Maintenance of glutathione systems (see Konorev et al, 1996). Glutathione in its reduced form (GSH) is an important factor in the prevention of damage by hydrogen peroxide. Hydrogen peroxide is a component of ischaemia-reperfusion injury and protection is afforded by the action of glutathione peroxidase and GSH. The importance of GSH and the pentose phosphate pathway in the chain reactions protecting the cell from free radical damage is illustrated in figure 1 from Zubairu et al, 1983.

(7) Endothelin inhibitors (see Goodwin et al, 1997; Pernow & Wang, 1997). Endothelin-1 (ET-1) is an extremely potent vasoconstrictor peptide derived from vascular endothelial cells. During and following myocardial ischaemia and reperfusion, the myocardial production and release of ET-1 is stimulated and the coronary constriction to ET-1 is enhanced. The pathophysiological role for ET-1 in the development of ischaemia has a strong basis and the potential for cardioprotective effects of ET-1 antagonists has been considered by Pernow and Wang (1997).

Ischaemia-reperfusion injury can arise in a wide range of conditions and the medicament can be used to treat these conditions. Examples include ischaemia because of myocardial infarct, during surgery (especially open heart surgery, or during organ transplantation), as a cardioplegia solution for heart or lung bypass surgery and in stroke. The medicament can also be used to ameliorate the effects of ischaemia in tissues, in particular as an anti-apoptotic agent to prevent cell death following ischaemia, e.g. muscle cell death.

In a further aspect, the present invention provides a method for preserving an organ for transplantation, the method comprising exposing the organ with a composition comprising an inositolphosphoglycan (IPG) and optionally one or more of the components mentioned above. As ischaemia is common in organs for transplantation, this approach is useful for preserving the energy level present in the organ prior to transplantation and during surgery. Conveniently, the composition can be perfused through the organ or used to store the organ prior to transplantation.

In a further aspect, the present invention provides compositions comprising a P-type IPG and ribose. In these compositions, the IPG drives mitochondrial oxidation and results in ATP generation from ADP without production of toxic byproducts. Preferably, the composition additionally comprises a purine or purine nucleotide precursor to provide the basic structural element of ATP. Other possible components of the composition are described above.

This composition is useful in organ preservation, in general surgery (e.g. as a perfusion fluid) and in other situations for the prevention or treatment of ischaemia in cells. Preferably, the composition is supplied as a powder or concentrate from which a liquid composition can be prepared. Alternatively, the composition can be supplied ready to use in as a liquid. Formulations and optional ingredients of the composition are discussed further below.

In further aspects, the present invention provides above compositions for use in a method of medical treatment, for example in the preparation of a medicament for the treatment of ischaemic conditions discussed above.

Embodiments of the present invention will now be described by way of example and not by limitation with reference to the accompanying drawings.

Brief Description of the Drawings

Figure 1 shows the correlation between the hepatic PRPP concentration and the log of ribose 5-phosphate and the flux through the oxidative pentose phosphate assay pathway (C1-C6) in different dietary and hormonal conditions in rats.

Figure 2 shows the correlation between the hepatic PRPP concentration and ATP and energy charge (EC), free cytosolic NAD^+/NADH and NAD^+/NADPH in different dietary and hormonal conditions in rats.

Figure 3 shows the correlation between the hepatic PRPP concentration and ADP, AMP and Pi in different dietary and hormonal conditions in rats.

Figures 4A and 4B shows the steady state concentration and the effect of insulin on extractable IPG A-type from the heart and other tissues from adult male rats. Figure 4A shows the results of a lipogenesis assay and figure 4B shows a cAMP-dependent protein kinase A assay. The solid columns show results in the absence of insulin, while the hatched columns show results 2 minutes after injection with insulin.

Figures 4C and 4D show the steady state concentration and the effect of insulin on extractable IPG P-type from heart and other tissues from adult male rats. Figure 4C shows a PDH phosphatase assay and figure 4D shows a cAMP-dependent protein kinase-P assay. The solid columns show results in the absence of insulin, while the hatched columns show results 2 minutes after injection with insulin.

Figures 4E and 4F show the results of a thymidine incorporation into EGF receptor transfected 3T3 cells, plotted against IPG A-type and IPG P-type concentrations respectively.

Figure 5 shows a schematic setting out the role of ribose, IPGs and selected substrates on the prevention or recovery from ischaemic damage according to the present invention.

Figure 6 shows a schematic setting out the site of action of IPG P-type in the activation of the PDH complex.

Detailed Description of the Invention

IPGs and IPG Analogues

Studies have shown that A-type mediators modulate the activity of a number of insulin-dependent enzymes such as cAMP dependent protein kinase (inhibits), adenylate cyclase (inhibits) and cAMP phospho-diesterases (stimulates). In contrast, P-type mediators modulate the activity of insulin-dependent enzymes such as pyruvate dehydrogenase phosphatase (stimulates) and glycogen synthase phosphatase (stimulates). The A-type mediators mimic the lipogenic activity of insulin on adipocytes, whereas the P-type mediators mimic the glycogenic activity of insulin on muscle. Both A-and P-type mediators are mitogenic when added to fibroblasts in serum free media. The ability of the mediators to stimulate fibroblast proliferation is enhanced if the cells are transfected with the EGF-receptor. A-type mediators can stimulate cell proliferation in the chick cochleovestibular ganglia.

Soluble IPG fractions having A-type and P-type activity have been obtained from a variety of animal tissues including rat tissues (liver, kidney, muscle brain, adipose, heart) and bovine liver. A- and P-type IPG

biological activity has also been detected in human liver and placenta, malaria parasitized RBC and mycobacteria. The ability of an anti-inositolglycan antibody to inhibit insulin action on human placental cytotrophoblasts and BC3H1 myocytes or bovine-derived IPG action on rat diaphragm and chick cochleovestibular ganglia suggests cross-species conservation of many structural features. However, it is important to note that although the prior art includes these reports of A- and P-type IPG activity in some biological fractions, the purification or characterisation of the agents responsible for the activity is not disclosed.

A-type substances are cyclitol-containing carbohydrates, also containing Zn^{2+} ion and optionally phosphate and having the properties of regulating lipogenic activity and inhibiting cAMP dependent protein kinase. They may also inhibit adenylate cyclase, be mitogenic when added to EGF-transfected fibroblasts in serum free medium, and stimulate lipogenesis in adipocytes.

P-type substances are cyclitol-containing carbohydrates, also containing Mn^{2+} and/or Zn^{2+} ions and optionally phosphate and having the properties of regulating glycogen metabolism and activating pyruvate dehydrogenase phosphatase. They may also stimulate the activity of glycogen synthase phosphatase, be mitogenic when added to fibroblasts in serum free medium, and stimulate pyruvate dehydrogenase phosphatase.

Methods for obtaining A-type and P-type IPGs are set out in Caro et al, 1997 and in WO97/02444 or WO97/02533.

The present invention also relates to inositol-containing IPG analogues, prepared using synthetic organic chemistry methods. Thus, by way of example, compound C3, 1D-6-O-(2-amino-2-deoxy-α-D-glucopyranosyl)-myo-inositol 1,2-

(cyclic phosphate), has been prepared previously, see Zapata et al, 1994. Compound C4, 1D-6-O-(2-amino-2-deoxy-α-D-glucopyranosyl)-chiro-inositol 1-phosphate can be synthesised as described in Jaramillo et al, 1994.

Pharmaceutical Compositions

Typically, the compositions of the invention can be formulated according to the specific application for which the composition is intended. The compositions may comprise, in addition to the one or more IPGs, and optionally one or more of the above components, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient(s). The precise nature of the carrier or other material may depend on the route of administration, e.g. intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes. For embodiment in which the medicaments or compositions of the invention are used in organ preservation, they can be formulated so that they are suitable for storing or perfusing organs or tissue.

The compositions may be supplied in the form of a powder or concentrate from which a composition can be prepared. Alternatively, the composition may be supplied in a ready to use form, e.g. as a liquid. In either event, the composition may include other active ingredients, adjuvants or carriers. Thus, physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

In embodiments in which the composition is used in the prophylactic or therapeutic treatment of conditions associated with a risk of ischaemia, preferably the

composition is administered to a patient via intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction. In this case, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as sodium chloride injection, Ringer's injection, lactated Ringer's injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required. Injection is a preferred mode of delivery for compositions for treating ischaemia that results from myocardial infarction, stroke or to treat or protect against apoptosis.

The active ingredients in the composition are preferable administered to an individual in preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

A composition may be administered alone or in combination with other treatments, either simultaneously or

sequentially dependent upon the condition to be treated.

Experimental

Experiments in this laboratory have shown with rat heart preparations that the tissue PRPP concentration in anoxic conditions fell and was partially restored by addition of ribose to the medium. Perhaps of greater significance was our observation for the decline in cellular PRPP in a range of tissues, including heart, in experimental diabetes (see Table 1). These data suggest that ribose or a ribose precursor and/or purine derivatives could advantageously be included in the medicaments compositions of the invention.

While reported effects of repletion of cardiac ATP are encouraging, it is apparent that these biosynthetic processes themselves require ATP, as does the reconversion of AMP to ADP and ATP, the required ATP being the very compound in short supply. Thus, any mechanism increasing the energy generating systems of the cell, primarily and most effectively via the mitochondrial oxidative restoration, would be advantageous to the process of cellular restoration. In this context, the regulation of the key enzyme for the entry of pyruvate into the tricarboxylic acid cycle, the pyruvate dehydrogenase complex, must be considered.

This enzyme is highly regulated by, among other factors, the energy status of the cell, by the NADH/NAD+ ratio and by the acetyl CoA/CoA ratio, via the interconversion of active/inactive forms of pyruvate dehydrogenase by phosphorylation/dephosphorylation reactions regulated by pyruvate dehydrogenase kinase and regulation of this enzyme complex at the pyruvate crossroads. This system operates in a manner such that ischaemic conditions activate PDH kinase dehydrogenase and so shut off energy production at this step. In order to circumvent this

inhibition, even in ischaemia, it is necessary to activate the PDH phosphatase and this can be accomplished by the presence of IPGs. Pyruvate dehydrogenase activity is the most important determinant of whether pyruvate is converted to lactate, leading to lactic acidosis and a low level of ATP from glycolysis, or whether the highly efficient ATP generating system of the tricarboxylic acid cycle will be facilitated.

The present proposal centres upon the use of naturally occurring activators of pyruvate dehydrogenase phosphatase, the inositol phosphoglycans, to promote the conversion of pyruvate dehydrogenase to the active form (Rademacher et al, 1994; Varela-Nieto et al, 1998), thereby enhancing the rephosphorylation of AMP and ADP. It is proposed that a combination of purine nucleotide precursors (to provide the basic structural element of the required ATP), together with ribose (to provide the ribose 5-phosphate for PRPP formation) and inositol phosphoglycans (to shift the pyruvate dehydrogenase complex towards the active form, generate energy and decrease lactic acidosis) would be a major new advance in the treatment of ischaemic heart conditions and loss of ATP. Such a therapy would supply all three major elements required for the restoration of the energy charge of the cell as shown in figure 5:

(1) Ribose, as the precursor of the synthesis of the adenine lost from the cell during extended ischaemia;

(2) PRPP, an essential component of the adenine biosynthetic pathway; and,

(3) An increase energy yield from carbohydrate fuel which can provide the energy needed for biosynthetic processes in (1) and (2) and also to re-

phosphorylate such ADP and AMP as remains in the cell to ATP.

The approach of using inositol phosphoglycans either alone or together with other precursors of adenine nucleotide synthesis and compounds protecting against loss of ATP (e.g. by inhibition of poly ADP ribose), in the treatment of ischaemic conditions in heart, kidney, brain or other organs, is a fundamental new approach to attempting to limit cell damage. In a preferred embodiment of the invention, the combination of ribose, purine precursors and nicotinamide, the latter to prevent lost of NAD and ATP by inhibition of polyADP ribose synthase, with the inositol phosphoglycans, the potent second messenger system functioning in the regulation of protein phosphorylation/dephosphorylation cycles, is a multifaceted attack on the very basis of cellular damage in ischaemic conditions, that is the loss of ATP.

Table 1 demonstrates that in diabetes, there is a drop in tissue levels of PRPP. This drop could make diabetic patients more at risk of morbidity following an ischaemic attack. It is well established that both the incidence and complications of coronary heart disease are elevated in diabetic patients and decreased tissue levels of PRPP could be the crucial link. Figure 1 demonstrates that tissue levels of ribose 5-phosphate are important in maintaining PRPP levels and figure 5 shows that ribose is the direct precursor of ribose 5-phosphate. Therefore, one important component in maintaining high levels of PRPP is to provide ribose as the precursor for ribose 5-phosphate.

Figures 2 and 3 demonstrate that in order to have high levels of PRPP in tissues, the cellular energy charge must be high. Under anoxic conditions, this is difficult since the enzyme PDH kinase is activated. The action of

this enzyme is to inactivate the PDH complex, which is involved in the biosynthesis of acetyl-CoA and NADH. The NADH so generated in the reperfusion period is oxidized by the electron transport chain to generate ATP. The acetyl-CoA is a substrate for the Krebs cycle in which one glucose can be oxidized to 36 ATPs via the generation of further NADH. The action of IPG-P type mediators is to activate PDH phosphatase which counteracts the PDH kinase and allows for activation of the PDH complex. This activation is shown in figure 6. The action of the IPG-P type and the amounts recovered from various tissues before and after insulin infusion are shown in figure 4C and D. In particular, an increase in activity is found in muscle and kidney upon insulin infusion. In contrast, decreased activity is found in heart, adipose tissue and brain (figure 4C). These data demonstrate that an insulin infusion could not substitute for a direct infusion of the IPG-P type. Figure 5 shows that an insulin infusion will also effect the IPG-A activity differentially in tissues and this unwanted effect would not occur on infusion of just IPG-P compound or its analogues.

References:

The following references are all expressly incorporated by reference.

Asplin et al, P.N.A.S., 90:5924-5928, 1993.

Berne, Amer. J. Physiol., 204:317-322, 1963.

Bouchard & Lamontagne, Cardiovasc. Res., 37:82-90, 1998.

Bozkurt et al, Cardiovasc. Surg., 5;117-124, 1997.

Bromme & Holz, Mol. Cell Biochem., 163-164:261-275, 1996.

Caro et al, Biochem. Molec. Med., 61:214-228, 1997.

Choong & Gavin, J. Cardiovasc. Surg. (Torino), 37:275-84, 1996.

Danforth et al, Circ. Res., 7:965-870, 1983.

de Jong et al, Eur. J. Pharmacol., 337:41-44, 1997.

Ferrari et al, Cardiovasc. Drugs Ther., 10:425-437, 1996.

Gilad et al, J. Mol. Cell Cardiol., 29:2585-2597, 1997.

Goodwin et al, Eur. J. Cardiothorac. Surg., 11:981-987, 1997.

Hillier et al, Amer. J. Epidemiol., 128:402-409, 1988.

Houston et al, J. Cell Mol. Cardiol., 29:1763-6, 1997.

Jaramillo et al, J. Org. Chem., 59:3135-3141, 1994.

Konorev et al, Br. J. Pharmacol., 199:511-8, 1996.

Kunjara et al, Biochem. J., 244:101-108, 1987.

Kunjara et al, In: Biopolymers and Bioproducts: Structure, Function and Applications, Ed Svati et al, 301-305, 1995.

Loh et al, Br. J. Pharmacol., 118:1905-12, 1996.

Mangano, J. Amer. Med. Assoc., 277:325-332, 1997.

Meldrum et al, Immunology, 92:472-477, 1997.

Muhlhauser et al, Diabetologia, 40:1492-1493, 1997.

Pernow & Wang, Cardiovasc. Res., 33:518-526, 1997.

Rademacher et al, Brazilian J. Med. Biol. Res., 27:327-341, 1994.

Russ et al, Pflugers Arch., 433:26-34, 1996.

Smits & Their, Diabetologia, 38:116-121, 1995.

Stanley et al, Cardiovasc. Res., 33:243-257, 1997.

Thiemermann et al, P.N.A.S.(USA), 94:679-683, 1997.

Varela-Nieto et al, Comp. Biochem. Physiol., 115:223-241, 1998

Zapata et al, Carbohydrate Res., 264;21-31, 1994.

Zimmer, J. Physiol. (Paris), 76:769-775, 1980.

Zimmer, Science, 220:81-82, 1983.

Zimmer, Mol. Cell Biochem., 160-161:101-109, 1996.

Zingarelli et al, Shock, 5:258-264, 1996.

Zubairu et al, J. Neurochemistry, 41:76-83, 1983.

TABLE 1. EFFECTS OF EXPERIMENTAL DIABETES ON PHOSPHORIBOSYL PYROPHOSPHATE (PRPP) CONTENT OF HEART AND OTHER TISSUES

	PHOSPHORIBOSYL PYROPHOSPHATE CONTENT (nmoles / g tissue)		
Tissue	Control	STZ Diabetic (14days)	"P"
Heart	3.61±0.11 (15)	2.60±0.20 (6)	<0.01
Liver	10.5±0.64 (17)	7.60±0.43 (5)	<0.001
Lung	5.40±0.05 (16)	3.44±0.39 (5)	<0.001
Testis	5.0±0.30 (20)	2.5±0.9 (5)	<0.02
Blood glucose (mM)	7.0± 0.45 (25)	28±3.0 (7)	<0.001
Body weight (g)	309±17 (20)	226±21 (7)	<0.01

The tissues were freeze-clamped and the PRPP content estimated as described by Kunjara et al (1987). The values are given as means ±SEM; Fisher's P values are given. The Adult male rats were used 14 days after the induction of diabetes with streptozotocin (Unpublished observations, Kunjara et al. 1992)

FIG 1 PRPP INCREASES WITH INCREASED RIBOSE 5-P

Correlation between the hepatic PRPP concentration and the log of ribose 5-phosphate and the flux through the oxidative pentose phosphate pathway (C1-C6) in different dietary and hormonal conditions



PRPP CONTENT OF LIVER

CONTROL FED RAT LIVER = 100%

FIG 2

PRPP IS HIGH WHEN THE CELLULAR ENERGY CHARGE IS HIGH

Correlation between the hepatic PRPP concentration and ATP and energy charge (EC), free cytosolic $NAD^+/NADH$ and $NADP^+/NADPH$ in different dietary and hormonal conditions



PRPP CONTENT OF LIVER

CONTROL FED RAT LIVER = 100%

FIG 3

PRPP IS LOW WHEN THE CELLULAR ENERGY CHARGE IS LOW

i.e: WHEN ADP AND AMP ARE HIGH

Correlation between the hepatic PRPP concentration and ADP, AMP, Pi in different dietary and hormonal conditions



PRPP CONTENT OF LIVER

CONTROL FED RAT LIVER = 100%

FIG 4 (A) & (B)

THE STEADY STATE CONCENTRATION AND THE EFFECT OF INSULIN ON THE EXTRACTABLE IPG A-TYPE FROM HEART AND OTHER TISSUES FROM ADULT MALE RATS



1unit is the amount of IPG A-type causing a 50% increase in the basal rate of lipogenesis or a 50% decrease in the activity of cAMP dependent protein kinase activity.

Solid columns- in abscenc of insulin
Hatched columns - 2 minutes after injection of insulin

FIG 4 (C) & (D)

THE STEADY STATE CONCENTRATION AND THE EFFECT OF INSULIN ON THE EXTRACTABLE IPG P-TYPE FROM HEART AND OTHER TISSUES FROM ADULT MALE RATS



1unit is the amount of IPG P-type causing a 50% increase in the activity of PDH phosphatase or a 50% decrease in the activity of cAMP dependent protein kinase activity.

Solid columns- in abscence of insulin
Hatched columns - 2 minutes after injection of insulin

FIG 4 (E) & (F)


HEART IPG A-TYPE
EFFECT ON THYMIDINE INCORPORATION INTO RC 3T3 CELLS
Increase in thymidine incorporation
60000
50000
40000
30000
20000
10000
0
FCS
Control
Insulin
B
1/320
1/160
1/80
1/40
Heart IPG A-type
Column 2 Contro
Column 4 Insulin


HEART IPG P-TYPE
EFFECT ON THYMIDINE INCORPORATION INTO RC 3T3 CELLS
Increase in thymidine incorporation
60000
50000
40000
30000
20000
10000
0
FCS
Insulin
Control
B
1/320
1/160
1/80
1/40
Heart IPG P-type
Column 2 Control
Column 4 Insulin

Figure 5

POSSIBLE ROLE OF RIBOSE. IPGs AND SELECTED SUBSTRATES ON PREVENTION / RECOVERY FROM ISCHAEMIC DAMAGE.



--ENERGY SOURCE--
Mitochondrial ox/phos
Pyruvate [lactate / alanine]

Activation of PDH P'ase by
.....IPGs.....

[Overcomes inhibition of enzyme in anoxic conditions and so promotes energy production.]

SITE OF ACTION OF IPG P-TYPE IN THE ACTIVATION OF THE PDH COMPLEX



Figure 6

PCT NO : GB /01499

Form 23/77 : 12/5/99

AGENT : Newham Ellis